| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/22/2022 | 201.51% | SVB Leerink | → $6 | Initiates Coverage On | → Outperform |
| 11/11/2022 | 302.01% | Needham | $10 → $8 | Maintains | Buy |
| 06/30/2022 | 402.51% | Needham | $8 → $10 | Maintains | Buy |
| 05/25/2022 | 402.51% | Oppenheimer | → $10 | Initiates Coverage On | → Outperform |
| 03/29/2022 | 402.51% | Aegis Capital | → $10 | Initiates Coverage On | → Buy |
| 11/11/2021 | 302.01% | Needham | $10 → $8 | Maintains | Buy |
| 08/13/2021 | 402.51% | Needham | $12 → $10 | Maintains | Buy |
| 08/14/2020 | 352.26% | SVB Leerink | $8 → $9 | Maintains | Outperform |
| 07/13/2020 | 503.02% | Needham | $18 → $12 | Maintains | Buy |
| 06/03/2019 | 804.52% | Needham | → $18 | Initiates Coverage On | → Buy |
| 06/03/2019 | 653.77% | BMO Capital | → $15 | Initiates Coverage On | → Outperform |
| 06/03/2019 | 905.03% | Stifel | → $20 | Initiates Coverage On | → Buy |
What is the target price for Trevi Therapeutics (TRVI)?
The latest price target for Trevi Therapeutics (NASDAQ: TRVI) was reported by SVB Leerink on November 22, 2022. The analyst firm set a price target for $6.00 expecting TRVI to rise to within 12 months (a possible 201.51% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Trevi Therapeutics (TRVI)?
The latest analyst rating for Trevi Therapeutics (NASDAQ: TRVI) was provided by SVB Leerink, and Trevi Therapeutics initiated their outperform rating.
When is the next analyst rating going to be posted or updated for Trevi Therapeutics (TRVI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Trevi Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Trevi Therapeutics was filed on November 22, 2022 so you should expect the next rating to be made available sometime around November 22, 2023.
Is the Analyst Rating Trevi Therapeutics (TRVI) correct?
While ratings are subjective and will change, the latest Trevi Therapeutics (TRVI) rating was a initiated with a price target of $0.00 to $6.00. The current price Trevi Therapeutics (TRVI) is trading at is $1.99, which is within the analyst's predicted range.